

FILO-COVIM - Observational study on the impact of the COVID-19 epidemic on patients with myeloproliferative neoplasms

Head :KILADJIAN Jean-Jacques, CIC 1427

Last update : 04/23/2021 | Version : 1 | ID : 73637

General

Identification

Detailed name	Observational study on the impact of the COVID-19 epidemic on patients with myeloproliferative neoplasms
---------------	--

Sign or acronym	FILO-COVIM
-----------------	------------

General Aspects

Medical area	Hematology
--------------	------------

Study in connection with Covid-19	Yes
-----------------------------------	-----

Health determinants	Genetic Healthcare system and access to health care services Medicine
---------------------	---

Scientific investigator(s) (Contact)

Name of the director	KILADJIAN
----------------------	-----------

Surname	Jean-Jacques
---------	--------------

Address	Centre d'Investigations Cliniques - Hôpital Saint-Louis - 75010 Paris
---------	---

Email	secretariat@filo-leucemie.org
-------	-------------------------------

Unit	CIC 1427
------	----------

Organization	Paris Public Hospitals (AP-HP); Inserm
--------------	--

Collaborations

Participation in projects, networks and consortia	Yes
---	-----

Funding

Governance of the database	
Sponsor(s) or organisation(s) responsible	FILO "French Innovative Leukemia Organization"
Organisation status	Public
Presence of scientific or steering committees	Yes
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	Describe the rate of serious Coronavirus infections in the different subgroups of patients with myeloproliferative neoplasms defined by ongoing treatment during the epidemic.
Inclusion criteria	Male or female aged 18 years and over Male or female patient with PV, ET, PMF or MF secondary to PV or ET diagnosed before the COVID-19 pandemic Attending an appointment from April 2020
Population type	
Age	Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	D45 - Polycythaemia vera

III - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

D47 - Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue

Gender Male
Woman

Geography area National

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 2020

Date of last collection (YYYY or MM/YYYY) 2021

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 2000

Data

Database activity Current data collection

Type of data collected Clinical data
Declarative data
Paraclinical data
Biological data

Clinical data (detail) Direct physical measures

Declarative data (detail) Face to face interview
Phone interview

Presence of a biobank No

Procedures

Followed pathology

Promotion and access

Promotion

Access